AGY Allergy Therapeutics Plc

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Group")

Allergy Therapeutics presents scientific findings from research portfolio at EAACI 2024

31 May 2024 Allergy Therapeutics plc (AIM: AGY), the integrated commercial biotechnology company specialising in allergy vaccines, today announces that it will be sharing key scientific findings from across its research portfolio at the European Academy of Allergy and Clinical Immunology (EAACI) Congress, taking place from today until 3 June 2024 in Valencia, Spain.  

The EAACI Congress is the world's largest scientific conference that specialises in the field of allergy and clinical immunology and the flagship meeting of the European Academy of Allergy and Clinical Immunology, an association of more than 16,000 clinicians, researchers and allied health professionals from 124 countries, dedicated to improving the health of people affected by allergic diseases.

Among its 12 posters being presented, Allergy Therapeutics will share:  

·      The positive results from the pivotal Phase III G306 trial, which evaluated the efficacy and safety of Grass MATA MPL, the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. The trial successfully met its primary endpoint, as previously announced on 14 November 2023. The findings from the G306 trial, alongside results of the earlier G309 exploratory field study, will support the Group's marketing authorisation application (MAA), with a planned submission in Q4 2024.

·      Results from analysis of patient and caregiver preferences for different venom and pollen immunotherapy approaches and their implications on adherence and treatment acceptance.

·      The beneficial safety and tolerability results from the healthy subject subcutaneous dosing cohorts of the Phase I/IIa PROTECT trial of the Group's novel virus-like-particle (VLP)-based peanut allergy vaccine candidate ("VLP Peanut"), without any major safety or tolerability findings. This ongoing trial progressed in March 2024 to subcutaneous dosing of peanut allergic patients, marking the start of the clinical proof of concept phase using biomarkers to assess preliminary efficacy.

Allergy Therapeutics will also be hosting a symposium, "Setting a new standard for grass subcutaneous immunotherapy," on Sunday, 2 June, 13:45-14:45 CEST, chaired by Professor Dr. Stefan Zielen, Head of the Institute for Respiratory Medicine, Frankfurt, Germany. The symposium will include presentations covering regulatory and clinical challenges in allergen immunotherapy trials, as well as results from the Group's pivotal Phase III G306 trial of Grass MATA MPL by key experts from the US and EU.

In addition, Prof. Mohamed Shamji from Imperial College, London and EAACI Vice President Congresses, will showcase the Group's scientific adaptive approaches to clinical development, as applied in the successful G309 and G306 studies, as examples of current state-of-the-art clinical development in a plenary session.

Finally, Prof. Shamji will host an embargo session at the closure day of the EAACI conference to release the Group's recently accepted VLP Peanut paper in the peer reviewed Journal of Allergy and Clinical Immunology, the official publication of the American Academy of Allergy, Asthma, and Immunology (AAAAI). This session will highlight the promising biomarker safety and efficacy profile of VLP Peanut, including the first clinical results supporting the hypo-allergic profile of VLP Peanut based on the skin test results from the PROTECT Phase I/IIa study.

Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, said: "At Allergy Therapeutics, our mission is to transform lives by breaking new ground in immunology treatments, and we are thrilled to have such a robust presence at this year's EAACI Congress. The research we are sharing demonstrates the strength of our science and, with one innovative short-course allergy immunotherapy targeting peanut allergy currently in the clinic and another targeting grass pollen allergy progressing towards a planned market authorisation application, we are steadfast in our commitment to helping patients change the way they think about their allergies and better manage their conditions."

The complete list of Allergy Therapeutics-sponsored abstracts accepted by EAACI for presentation are available on the Group's website.

No new material price sensitive information is expected to be disclosed on Allergy Therapeutics at the EAACI Congress 2024.

ENDS

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

Panmure Gordon (Nominated Adviser and Broker)

Emma Earl, Freddy Crossley, Mark Rogers, Corporate Finance

Rupert Dearden, Corporate Broking

+44 (0)20 7886 2500

ICR Consilium

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@consilium-comms.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.